Antioxidant Treatment Strategies: Photobiomodulation in Pain Management and Tissue Regeneration

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 4436

Special Issue Editors

Department of Surgical Sciences and Integrated Diagnostics, Laser Centre Therapy, University of Genoa, 16132 Genoa, Italy
Interests: laser therapy; photobiomodulation; restorative dentistry; dental implantology
Special Issues, Collections and Topics in MDPI journals
1. Department of Surgical Sciences and Integrated Diagnostics, Laser Centre Therapy, University of Genoa, 16132 Genoa, Italy
2. Department of Continuous Professional Developmental, UCL-Eastman Dental Institute, London WC1E 6DE, UK
Interests: laser therapy; photobiomodulation; laser–tissue interaction; oral surgery; oral medicine and pathology; orofacial neuropathic pain; bone regeneration
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The human antioxidant system works as a complex unit to regulate reactive oxygen species (ROS). Cellular antioxidant defenses usually maintain ROS/reactive nitrogen species (RNS) at concentrate level, preventing excess oxidation of cellular molecules. Mitochondrial dysfunction can result in a reduction in the synthesis of high-energy molecules such as adenosine triphosphate (ATP). Given the crucial role of the mitochondrial organelle, organs and tissues require an effective antioxidant therapy to illuminate the mitochondria to augment ATP production and regulate ROS and nitric oxide to restore mitochondrial function. In this context, photobiomodulation therapy has emerged in the management of various mitochondrial dysfunction diseases/conditions and adverse effects resulting from various oncology treatments, in terms of pain alleviation and acceleration of tissue repair and regeneration.

The aim of this Special Issue is to underline the advances of photobiomodulation in the fields of medicine and dentistry, as a therapeutic treatment modality in pain management and tissue regeneration.

Both original research papers and review papers are welcome. Technical topics include but are not limited to the following:

  • Effects of photobiomodulation on pain management;
  • Role of light therapy in dental hypersensitivity;
  • Influence of photobiomodulation therapy in bone healing and regeneration of various bone defects;
  • Role of photobiomodulation parameters in optimizing better outcomes in bone regeneration;
  • Effects of photobiomodulation on accelerating acute and chronic wound healing;
  • Photobiomodulation therapy and its influence on dental implant integration;
  • Impact of photobiomodulation on mitochondrial dysfunction conditions/diseases;
  • Photobiomodulation therapy and its role in orofacial neuropathic pain management;
  • Advanced understanding of photobiomodulation as an antioxidant in cellular repair;
  • Photobiomodulation therapy in oral mucosal lesion management.

Prof. Dr. Stefano Benedicenti
Prof. Dr. Reem Hanna
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Photobiomodulation
  • Pain management
  • Dental hypersensitivity
  • Bone regeneration
  • Wound healing
  • Tissue regeneration
  • Dental implant
  • Mitochondrial dysfunction conditions/diseases
  • Orofacial neuropathic pain
  • Oxidative stress
  • Oral mucosal lesions

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

28 pages, 6920 KiB  
Article
Outpatient Oral Neuropathic Pain Management with Photobiomodulation Therapy: A Prospective Analgesic Pharmacotherapy-Paralleled Feasibility Trial
by Reem Hanna, René Jean Bensadoun, Seppe Vander Beken, Patricia Burton, James Carroll and Stefano Benedicenti
Antioxidants 2022, 11(3), 533; https://0-doi-org.brum.beds.ac.uk/10.3390/antiox11030533 - 10 Mar 2022
Cited by 13 | Viewed by 3736
Abstract
Neuropathic pain (NP) can be challenging to treat effectively as analgesic pharmacotherapy (MED) can reduce pain, but the majority of patients do not experience complete pain relief. Our pilot approach is to assess the feasibility and efficacy of an evidence-based photobiomodulation (PBM) intervention [...] Read more.
Neuropathic pain (NP) can be challenging to treat effectively as analgesic pharmacotherapy (MED) can reduce pain, but the majority of patients do not experience complete pain relief. Our pilot approach is to assess the feasibility and efficacy of an evidence-based photobiomodulation (PBM) intervention protocol. This would be as an alternative to paralleled standard analgesic MED for modulating NP intensity-related physical function and quality of life (QoL) prospectively in a mixed neurological primary burning mouth syndrome and oral iatrogenic neuropathy study population (n = 28). The study group assignments and outcome evaluation strategy/location depended on the individual patient preferences and convenience rather than on randomisation. Our prospective parallel study aimed to evaluate the possible pre/post-benefit of PBM and to allow for a first qualitative comparison with MED, various patient-reported outcome measures (PROMs) based on Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT-II) were used for up to a nine-month follow-up period in both intervention groups (PBM and MED). The PBM protocol applied to the PBM group was as follows: λ810 nm, 200 mW, 0.088 cm2, 30 s/point, 9 trigger and affected points, twice a week for five consecutive weeks, whereas the MED protocol followed the National Institute of Clinical Excellence (NICE) guidelines. Our results showed that despite the severe and persistent nature of the symptoms of 57.50 ± 47.93 months at baseline in the PBM group, a notably rapid reduction in PISmax on VAS from 7.6 at baseline (T0) to 3.9 at one-month post-treatment (T3) could be achieved. On the other hand, mean PISmax was only reduced from 8.2 at baseline to 6.8 at T3 in the MED group. Our positive PBM findings furthermore support more patients’ benefits in improving QoL and functional activities, which were considerably impaired by NP such as: eating, drinking and tasting, whereas the analgesic medication regimens did not. No adverse events were observed in both groups. To the best knowledge of the authors, our study is the first to investigate PBM efficacy as a monotherapy compared to the gold standard analgesic pharmacotherapy. Our positive data proves statistically significant improvements in patient self-reported NP, functionality, psychological profile and QoL at mid- and end-treatment, as well as throughout the follow-up time points (one, three, six and nine months) and sustained up to nine months in the PBM group, compared to the MED group. Our study, for the first time, proves the efficacy and safety of PBM as a potent analgesic in oral NP and as a valid alternative to the gold standard pharmacotherapy approach. Furthermore, we observed long-term pain relief and functional benefits that indicate that PBM modulates NP pathology in a pro-regenerative manner, presumably via antioxidant mechanisms. Full article
Show Figures

Figure 1

Back to TopTop